Literature DB >> 27108265

Pay attention to cardiac remodeling in cancer cachexia.

Yawen Zheng1, Han Chen2, Xiaoqing Li3, Yuping Sun4.   

Abstract

Cancer cachexia is a complex and multifaceted disease state characterized by fatigue, weakness, and loss of skeletal muscle and adipose tissue. Recently, the profound negative effects of cancer cachexia on cardiac tissue draw much attention, which is likely to contribute to mortality in tumor-bearing animals. The mechanism of cardiac remodeling is not so clear and involved with a series of molecular alterations. In cancer cachexia model, progressive loss of left ventricular mass and decrease in myocardial function is observed and cardiac autonomic functions are altered. Levels of several emerging cardiovascular neurohormones are found elevating in patients with cancer, but it is still controversial whether the changes could reflect the heart injury accurately. The remedy for cardiac remodeling has been explored. It is showed that exercise can modulate signaling pathways activated by wasting cytokines and impact on the resulting outcomes on heart adaptation. Some drugs, such as bisoprolol, spironolactone, perindopril, tandospirone, and simvastatin, can mitigate adverse effects of the tumor on the heart and prolong survival.

Entities:  

Keywords:  Cancer cachexia; Cardiac remodeling; Cardiovascular neurohormones; Treatment pathway

Mesh:

Year:  2016        PMID: 27108265     DOI: 10.1007/s00520-016-3222-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  54 in total

1.  Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.

Authors:  Xiaolan Zhou; Jin Lin Wang; John Lu; Yanping Song; Keith S Kwak; Qingsheng Jiao; Robert Rosenfeld; Qing Chen; Thomas Boone; W Scott Simonet; David L Lacey; Alfred L Goldberg; H Q Han
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

2.  Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia.

Authors:  Yulia Elkina; Sandra Palus; Anika Tschirner; Kai Hartmann; Stephan von Haehling; Wolfram Doehner; Ulrike Mayer; Andrew J S Coats; John Beadle; Stefan D Anker; Jochen Springer
Journal:  Int J Cardiol       Date:  2013-10-12       Impact factor: 4.164

Review 3.  Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review.

Authors:  Trude R Balstad; Tora S Solheim; Florian Strasser; Stein Kaasa; Asta Bye
Journal:  Crit Rev Oncol Hematol       Date:  2014-03-12       Impact factor: 6.312

4.  Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.

Authors:  Scott Shadfar; Marion E Couch; Kibwei A McKinney; Lisa J Weinstein; Xiaoying Yin; Jessica E Rodríguez; Denis C Guttridge; Monte Willis
Journal:  Nutr Cancer       Date:  2011-06-09       Impact factor: 2.900

5.  Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice.

Authors:  Min Tian; Michelle L Asp; Yoshinori Nishijima; Martha A Belury
Journal:  Int J Oncol       Date:  2011-08-05       Impact factor: 5.650

6.  Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia.

Authors:  Raymond D Devine; Sabahattin Bicer; Peter J Reiser; Markus Velten; Loren E Wold
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-19       Impact factor: 4.733

Review 7.  Cancer drugs and the heart: importance and management.

Authors:  Thomas M Suter; Michael S Ewer
Journal:  Eur Heart J       Date:  2012-07-12       Impact factor: 29.983

8.  Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia.

Authors:  Sandra Palus; Stephan von Haehling; Valerie C Flach; Anika Tschirner; Wolfram Doehner; Stefan D Anker; Jochen Springer
Journal:  Int J Cardiol       Date:  2013-05-13       Impact factor: 4.164

Review 9.  Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure.

Authors:  Corinna Bergamini; Mariantonietta Cicoira; Andrea Rossi; Corrado Vassanelli
Journal:  Eur J Heart Fail       Date:  2009-04-04       Impact factor: 15.534

10.  The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.

Authors:  Rodrigo Moore-Carrasco; Sílvia Busquets; Vanessa Almendro; Moorthy Palanki; Francisco J López-Soriano; Josep M Argilés
Journal:  Int J Oncol       Date:  2007-05       Impact factor: 5.884

View more
  6 in total

Review 1.  Effects of ionizing radiation on the heart.

Authors:  Marjan Boerma; Vijayalakshmi Sridharan; Xiao-Wen Mao; Gregory A Nelson; Amrita K Cheema; Igor Koturbash; Sharda P Singh; Alan J Tackett; Martin Hauer-Jensen
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-10       Impact factor: 5.657

Review 2.  Cardiac Complications: The Understudied Aspect of Cancer Cachexia.

Authors:  Vivek Bora; Bhoomika Patel
Journal:  Cardiovasc Toxicol       Date:  2022-02-16       Impact factor: 3.231

3.  PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction.

Authors:  Brent A McLean; Vaibhav B Patel; Pavel Zhabyeyev; Xueyi Chen; Ratnadeep Basu; Faqi Wang; Saumya Shah; Bart Vanhaesebroeck; Gavin Y Oudit
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

Review 4.  Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.

Authors:  Madison Pereira; Kathy Matuszewska; Alice Glogova; Jim Petrik
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

Review 5.  Targeting cancer cachexia: Molecular mechanisms and clinical study.

Authors:  Yong-Fei Wang; Zi-Yi An; Dong-Hai Lin; Wei-Lin Jin
Journal:  MedComm (2020)       Date:  2022-09-10

6.  Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Rudolf A de Boer; Jean-Sébastien Hulot; Carlo Gabriele Tocchetti; Joseph Pierre Aboumsallem; Pietro Ameri; Stefan D Anker; Johann Bauersachs; Edoardo Bertero; Andrew J S Coats; Jelena Čelutkienė; Ovidiu Chioncel; Pierre Dodion; Thomas Eschenhagen; Dimitrios Farmakis; Antoni Bayes-Genis; Dirk Jäger; Ewa A Jankowska; Richard N Kitsis; Suma H Konety; James Larkin; Lorenz Lehmann; Daniel J Lenihan; Christoph Maack; Javid J Moslehi; Oliver J Müller; Patrycja Nowak-Sliwinska; Massimo Francesco Piepoli; Piotr Ponikowski; Radek Pudil; Peter P Rainer; Frank Ruschitzka; Douglas Sawyer; Petar M Seferovic; Thomas Suter; Thomas Thum; Peter van der Meer; Linda W Van Laake; Stephan von Haehling; Stephane Heymans; Alexander R Lyon; Johannes Backs
Journal:  Eur J Heart Fail       Date:  2020-11-12       Impact factor: 15.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.